Non-exclusive rebate agreement for the active ingredient Brinzolamide + Brimonidine
Non-exclusive rebate agreement for the active ingredient Brinzolamide + Brimonidine (ATC S01EC24): Conclusion of a framework agreement for pharmaceutical companies under equal conditions, with accession possible at any time. The contract duration is from 01.09.2026 to 31.08.2028, with an extension option of 1x12 months. Required documents for contract conclusion or later accession include an offer letter, acceptance of DAK-Gesundheit's contractual terms and rebates, and completed Annexes 1 and 2 (listing the medicines to be covered). Submission of documents is via email to openhouse@dak.de, with Annex 2 to be sent as an Excel file. For a contract start on 01.09.2026 or later accession on the 1st or 15th of a month, documents must be submitted by the 5th of the preceding month. This procedure does not fall under cartel procurement law and automatically ends upon the entry into force of an exclusive contract for the active ingredient Brinzolamide + Brimonidine.
CONTRACTING AUTHORITY
Name
DAK-Gesundheit
City
Hamburg
Country
DE
CLASSIFICATION
Procedure Type
Open Procedure
Contract Type
Supplies
Main CPV
33600000, Pharmaceutical products.
ADDITIONAL DETAILS
EU Funded
Yes
Suitable for SMEs
No
Electronic Submission
Required
Legal Basis
32014L0024
DEADLINES & TIMELINE
Submission Deadline
1085 days remaining(LOT-0001)
Published